Alto Neuroscience (NYSE:ANRO) Reaches New 12-Month High on Earnings Beat

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price reached a new 52-week high during trading on Wednesday after the company announced better than expected quarterly earnings. The stock traded as high as $29.70 and last traded at $29.19, with a volume of 97651 shares. The stock had previously closed at $28.78.

The company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.08.

Analyst Upgrades and Downgrades

Several brokerages have commented on ANRO. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. BTIG Research upped their price target on Alto Neuroscience from $28.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday. Zacks Research lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 22nd. Wolfe Research assumed coverage on Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating for the company. Finally, Wedbush raised their target price on Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.62.

Institutional Trading of Alto Neuroscience

Institutional investors have recently made changes to their positions in the company. Quantinno Capital Management LP grew its position in Alto Neuroscience by 1.4% in the first quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after acquiring an additional 490 shares during the period. Torren Management LLC purchased a new stake in Alto Neuroscience in the 4th quarter valued at about $62,000. XTX Topco Ltd boosted its stake in Alto Neuroscience by 32.2% during the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the period. Renaissance Technologies LLC boosted its position in shares of Alto Neuroscience by 6.3% during the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after purchasing an additional 6,100 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock valued at $884,000 after buying an additional 8,148 shares during the period.

Alto Neuroscience Price Performance

The stock’s 50 day simple moving average is $25.70 and its 200-day simple moving average is $22.68. The company has a market capitalization of $1.15 billion, a PE ratio of -13.53 and a beta of 1.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.